

## Review

## Nitro-Fatty Acid Logistics: Formation, Biodistribution, Signaling, and Pharmacology

Francisco J. Schopfer<sup>1,\*</sup> and Nicholas K.H. Khoo<sup>1,\*</sup>

**In addition to supporting cellular energetic demands and providing building blocks for lipid synthesis, fatty acids (FAs) are precursors of potent signaling molecules. In particular, the presence of conjugated double bonds on the fatty-acyl chain provides a preferential target for nitration generating nitro-FAs (NO<sub>2</sub>-FAs). The formation of NO<sub>2</sub>-FAs is a nonenzymatic process that requires reactive nitrogen species and occurs locally at the site of inflammation or during gastric acidification. NO<sub>2</sub>-FAs are electrophilic and display pleiotropic signaling actions through reversible protein alkylation. This review focuses on the endogenously formed NO<sub>2</sub>-FAs' mechanism of absorption, systemic distribution, signaling, and preclinical models. Understanding the dynamics of these processes will facilitate targeted dietary interventions and further the current pharmacological development aimed at low-grade inflammatory diseases.**

**Diet, FAs, and Signaling**

It has been almost 90 years since the pioneering discovery that some FAs are essential dietary components [1,2]. These findings demonstrated that both linoleic acid (LA) and  $\alpha$ -linolenic acid ( $\alpha$ LA) are essential FAs, as animals lack  $\Delta$ -12 and  $\Delta$ -15 desaturases required for their synthesis. Deficiency of these FAs in early parenteral formulations led to severe dermatitis [3,4]. Thus, not only do FAs serve as energy sources but are also critical structural components of membranes and signaling molecules, with LA and  $\alpha$ LA serving as precursors to arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. Bioactive signaling mediators are generated using these FAs as substrates through the oxidative action of cyclooxygenases, lipoxygenases, and cytochrome P450 activity [5]. In addition to providing essential bis-allylic FAs, diets also provide other important FAs that have conjugated double bonds such as **conjugated linoleic- and linolenic-acids (CLA and CLnA, respectively; see Glossary)** [6]. CLA and CLnA are ruminant-derived FAs present in meat and dairy products [7]. Additionally, other CLnA isomers are acquired from plant sources such as pomegranate and bitter melon [8]. Alternatively, the microbiome participates in the isomerization of LA into CLA, contributing to the systemic CLA levels [9]. While conjugated FAs are not used as substrates during enzymatic conversion to bioactive lipids, the lipoxygenase-driven oxidation of polyunsaturated FAs results in the conjugation of double bonds. Moreover, the sequential oxidation of arachidonic, eicosapentaenoic, and docosahexaenoic acids by lipoxygenases and other oxidases leads to oxidized bioactive FAs that can contain multiple conjugated double bonds (e.g., lipoxins, leukotrienes, maresins, and resolvins) [5]. The presence of conjugated double bonds in the alkyl chain is essential for **nitration** reactions as it largely increases the efficiency of the reaction and yields of nitrated products [10]. Nonetheless, oxidized FAs containing conjugated double bonds or bis-allylic carbons are not endogenous substrates of nitration reactions. While most pharmacological efforts focus on nitrated oleic acid (**nitro-oleic acid, NO<sub>2</sub>-OA**), human data show that endogenous nitration reactions occur almost exclusively on conjugated FAs [11,12]. This review covers FA nitration (focusing predominantly on conjugated FAs), mechanisms of absorption and distribution of **nitro-fatty acids (NO<sub>2</sub>-FA)**, and the protective effects of endogenously formed NO<sub>2</sub>-FAs. Additionally, preclinical

## Highlights

Nitro-fatty acids (NO<sub>2</sub>-FAs) are endogenously formed through nonenzymatic mechanisms that require conjugated fatty acids (FAs) and nitrogen dioxide (\*NO<sub>2</sub>), a reactive oxidation product of nitrite and nitric oxide (\*NO). NO<sub>2</sub>-FAs are formed in the gastric compartment, at sites of inflammation and during ischemia-reperfusion.

Nitro-conjugated linoleic acid (NO<sub>2</sub>-CLA) is the most abundant endogenously-formed NO<sub>2</sub>-FA and nitro oleic acid (NO<sub>2</sub>-OA) is a synthetic NO<sub>2</sub>-FA being developed as a drug.

NO<sub>2</sub>-FAs exert cell signaling responses through their electrophilic reactivity by reversibly modifying cysteine residues. NO<sub>2</sub>-FAs regulate signaling activities, mainly through the activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), heat shock response, and inhibition of NF- $\kappa$ B signaling.

NO<sub>2</sub>-FAs are distributed to tissues and esterified to triglycerides.

Endothelium is both protected by NO<sub>2</sub>-FAs and provides the necessary mechanism and regulation to transport NO<sub>2</sub>-FAs to surrounding tissues.

NO<sub>2</sub>-FAs have been shown to be effective in a large range of preclinical animal models.

<sup>1</sup>Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA

\*Correspondence: fjs2@pitt.edu (F.J. Schopfer) and nkhoop@pitt.edu (N.K.H. Khoo).



animal data on pharmacological approaches to treat a variety of diseases (Figure 1) instigated by inflammatory, oxidative stress, and fibrotic processes are discussed.

### Let the Chemistry Explain the Biology

The discovery of nitrotyrosine as a hallmark of peroxynitrite formation, oxidative stress, and later, nitration induced by the activity of peroxidases (e.g., myeloperoxidase, eosinophil peroxidase, and lactoperoxidase), led to efforts to find additional modifications of biomolecules that could be either pathological biomarkers or drive disease pathogenesis [13]. As a consequence of these efforts, nitration of oligonucleotides, catecholamines, and lipids was described, with the first two groups of biomolecules leading to the formation of 8-nitro-guanidine, 8-nitro-guanosine, 8-nitro-cGMP, 6-nitro-dopamine, and 6-nitro-epinephrine, among others [14,15]. While the nitration of DNA and RNA bases is associated with inflammation, the formation of NO<sub>2</sub>-cGMP has been studied and shown to exert cellular redox, vascular, and signaling functions [16]. With regards to lipids, initial efforts were hindered by analytical limitations and low instrument sensitivity. OA and LA were initially reported as *in vivo* lipid nitration targets [17–22]. These findings and interpretations were later revised when Bonacci *et al.* reported that the yields obtained from the nitration of CLA were >10<sup>5</sup> times higher than those of nonconjugated dienes, and that **nitro-conjugated linoleic acid (NO<sub>2</sub>-CLA)** was the most abundant endogenously formed NO<sub>2</sub>-FA [10]. The identification of the endogenous substrate permitted the evaluation of the biological conditions under which these were formed, the characterization of the concentrations, metabolism, and signaling properties [23].

The mechanism involved in tyrosine nitration starts with an initial one-electron oxidation [e.g., by hydroxyl-, carbonate-, lipid-peroxyl-, lipid-alkoxyl- and nitrogen dioxide (<sup>•</sup>NO<sub>2</sub>)-radicals] [13], generating a tyrosyl radical that is further stabilized by resonance [13]. This is followed by a radical-radical coupling reaction between the tyrosyl radical and <sup>•</sup>NO<sub>2</sub> to form nitrotyrosine (Figure 2A). The product of tyrosine nitration is stable and occurs mainly in proteins, conveying biological activity through the modification of the physicochemical properties of the tyrosine residues that occur when the nitro group is incorporated. This causes a significant decrease in the pKa of the tyrosine hydroxyl group induced by the strong electron withdrawing characteristics of the adjacent nitro group [13].

The nitration of GTP also proceeds through an initial one-electron oxidation with hydrogen abstraction that is stabilized by resonance (between C5 and C8 radicals). The radical at C8 reacts with <sup>•</sup>NO<sub>2</sub> to restore the aromatic purine ring leading to the formation of 8-NO<sub>2</sub>-GTP. Through the enzymatic activity of guanylate cyclase, 8-NO<sub>2</sub>-GTP is converted into the electrophilic product 8-NO<sub>2</sub>-cGMP, which reacts with protein thiols through nucleophilic substitution releasing the nitro group (Figure 2B). This reaction forms a stable Cys-cGMP adduct; a process termed protein S-guanylation. When compared to other endogenous electrophiles, the reactivity of 8-NO<sub>2</sub>-cGMP with glutathione (GSH) is low with a second-order rate constant of 0.03 m<sup>-1</sup> s<sup>-1</sup>. This is orders of magnitude slower than the reaction constants determined for other biologically relevant electrophiles such as 4-hydroxynonenal, 15-deoxy-prostaglandin J2, NO<sub>2</sub>-OA, nitro-linoleic acid (NO<sub>2</sub>-LA), and NO<sub>2</sub>-CLA (reaction constants of 1.3, 0.7, 355, 183, and 34 m<sup>-1</sup> s<sup>-1</sup>, respectively) [24–26]. Most of the biologically relevant electrophiles are rapidly detoxified through the enzymatic activity of glutathione S-transferases [27]. By contrast, the conjugation reaction between 8-NO<sub>2</sub>-cGMP and GSH has not been reported to be catalyzed by glutathione S-transferases [28].

Nitration reactions of FAs occur when a nitro group is added to an alkyl chain. One mechanism involves a direct radical-radical reaction between <sup>•</sup>NO<sub>2</sub> and an alkyl radical (resembling the second step of tyrosine nitration) [29]. This route will not be covered in this review as it lacks

### Glossary

**Conjugated linoleic acid (CLA):** FA characterized by having an 18 carbon alkyl chain containing two conjugated double bonds. Derived from ruminants and mainly found in meat and dairy products. The preferred endogenous substrate for gastric, metabolic and inflammatory-mediated FA nitration.

**Conjugated linolenic acid (CLnA):** FA characterized by having 18 carbon and two or three conjugated double bonds. The *cis-trans* configuration and position of the double bonds greatly depend on its biological source. CLnA containing three conjugated double bonds is mainly found in plant-derived oils. Bitter melon and pomegranate are the most common sources of plant-derived dietary CLnA. CLnA containing two conjugated double bonds is most commonly found in dairy products.


**Nitration:** reaction that encompasses the addition of a nitro group (-NO<sub>2</sub>) to an organic compound or macromolecule.

**Nitro-conjugated linoleic acid (NO<sub>2</sub>-CLA):** the most abundant endogenously formed NO<sub>2</sub>-FA. It is biologically formed as two isomers characterized by the NO<sub>2</sub> group located in carbons 9 or 12 that display equivalent signaling potency.

**Nitro-fatty acid (NO<sub>2</sub>-FA):** electrophilic bioactive FAs that contain a nitro group (-NO<sub>2</sub>) and display anti-inflammatory, antioxidant, and antifibrotic cell signaling properties, mainly through reactions with cysteines.

**Nitro-oleic acid (NO<sub>2</sub>-OA):** predominant NO<sub>2</sub>-FA isomer used in preclinical animal models. CXA-10 which corresponds to NO<sub>2</sub>-OA with the NO<sub>2</sub> group located on carbon 10, is currently undergoing Phase II clinical trials.


**Nitrosation:** addition of a nitroso group to an organic compound or macromolecule.



## Trends in Endocrinology &amp; Metabolism

**Figure 1. Overview of  $\text{NO}_2\text{-FA}$  Formation, Distribution, Metabolism, Signaling, and Protection.**  $\text{NO}_2\text{-FAs}$  are mainly formed in the gastric compartment and, upon absorption and distribution, exert protective effects by activating antioxidant, anti-inflammatory, and antifibrotic signaling pathways.  $\text{NO}_2\text{-FAs}$  are finally metabolized and eliminated, at least partially, through kidney filtration. Abbreviations: HSP, heat shock protein; NF- $\kappa$ B, nuclear factor- $\kappa$ B;  $\text{NO}_2\text{-FA}$ , nitro-fatty acid; Keap1, kelch-like ECH-associated protein 1; Nrf2, nuclear factor (erythroid-derived 2)-like 2; TG, triglyceride.

biological relevance, nitration yields are very low, and no derivatives of these reactions have been observed *in vivo* [29]. The biologically relevant nitration reactions typically involve the direct addition of  $\cdot\text{NO}_2$  to the double bond (Figure 2C). This addition reaction is reversible and occurs with all double bonds yielding a  $\beta$ -nitroalkyl radical. Under most biological conditions, these unstable radicals eliminate  $\cdot\text{NO}_2$  (reverse reaction) inducing *cis-trans* isomerizations of the double bond (Figure 2C). When these reactions occur on lipids containing conjugated double bonds, the initial radical is stabilized by resonance, which decreases the rate of the elimination reaction and favors reactions with oxygen and nitrogen oxides (e.g.,  $\cdot\text{NO}_2$  and  $\cdot\text{NO}$ ) producing intermediates that decompose to form electrophilic nitroalkenes (e.g.,  $\text{NO}_2\text{-CLA}$ ; Figure 2D) [10].



Trends in Endocrinology &amp; Metabolism

**Figure 2. Mechanism of Biologically Relevant Nitration Reactions.** (A) Tyrosine nitration: a one-electron oxidation of tyrosine leads to the formation of a tyrosyl radical, which is stabilized by resonance. A radical-radical reaction between the tyrosyl radical and  $^*\text{NO}_2$  results in the formation of nitrotyrosine. Nitrotyrosine is not reactive and exerts its biological activity by inducing protein conformational changes induced by charge and spatial modifications. (B) Formation of 8- $\text{NO}_2$ -cGMP: 8-nitro-cGMP is formed upon the activity of guanylate cyclase on  $\text{NO}_2$ -GTP. GTP levels in cells largely exceed the amount of cGMP and as a consequence are the preferred biological substrate for purine nitration. Nitration of GTP is initiated by one-electron oxidation to form a radical that can be stabilized by resonance. As for the tyrosyl radical, a radical-radical reaction with  $^*\text{NO}_2$  forms  $\text{NO}_2$ -GTP. 8- $\text{NO}_2$ -cGMP reacts slowly and irreversibly with thiols with the concomitant release of nitrite. (C) Nitration of monounsaturated and bis-allylic FAs: this nitration mechanism is inefficient as the initial addition of  $^*\text{NO}_2$  results in an unstable radical. The radical intermediate reverses back to the alkene with the elimination of  $^*\text{NO}_2$ , usually resulting in *cis-trans* isomerization of the double bond. This reaction renders  $\text{NO}_2$ -FAs only in the presence of high concentrations of  $^*\text{NO}_2$ . (D) Nitration of conjugated dienes:  $^*\text{NO}_2$  adds to the double bond and the resulting radical is also stabilized by resonance. This radical is then oxidized to form a  $\text{NO}_2$ -FA with conjugated double bonds. The resulting molecule contains two electrophilic carbons, and thiols can add reversibly via Michael addition reaction to the  $\beta$  and  $\delta$  carbon. Abbreviation:  $\text{NO}_2$ -FA, nitro-fatty acid.

### Main Sites of $\text{NO}_2$ -CLA Formation

A strong rationale supported by the nitration chemistry and potential physiological actions of nitrated compounds motivated studies to evaluate the mechanisms and sites of endogenous  $\text{NO}_2$ -FA formation. The first evidence of endogenous  $\text{NO}_2$ -CLA formation in pathological

conditions was observed in a mouse model of heart ischemia–reperfusion (I/R). Although initially identified as a *trans*-NO<sub>2</sub>-LA given its increased retention time compared to *cis*-NO<sub>2</sub>-LA synthetic standards [30], this observation was later corrected, and definitive chemical assignment was provided using isotopically labeled NO<sub>2</sub>-CLA standards and HPLC-MS/MS analysis [10]. Historically, nitration reactions were strongly linked to inflammation driving initial detection efforts to endogenous sites where proinflammatory and oxidative conditions would prevail. Thus, the role of phagocytic cells, mitochondria, I/R events, and acute and chronic inflammation was investigated [10]. The evaluation of NO<sub>2</sub>-CLA formation proved difficult; the main reason being the electrophilic nature displayed by NO<sub>2</sub>-FAs and their reactivity towards thiols. If the concentration of nucleophilic intracellular targets, which range from 2 mM to 17 mM for GSH and from 10 mM to 50 mM for protein thiols [31,32], is considered, >99% of NO<sub>2</sub>-CLA would be predicted to be covalently bound to cysteine through Michael addition reactions in cells [26]. Advances in the investigation of the local formation of these species have been limited by the inherent difficulty to accurately quantify the adducted fraction [33]. In addition, the local formation has yet to be shown to impact systemic levels measured in circulation.

### **In Vivo Nitration**

Over the past 15 years, it has become clear that NO<sub>2</sub> is an active inorganic anion that mediates vasodilation, induces **nitrosation** and participates in nitration reactions [34,35]. Nitrite is a product of •NO oxidation that can also be acquired through diet or be formed in the oral cavity after reduction of dietary nitrate by commensal bacteria [36]. The low pH gastric compartment of the stomach provides ideal conditions for NO<sub>2</sub> protonation, generating different nitrogen oxides including dinitrogen trioxide (N<sub>2</sub>O<sub>3</sub>) and •NO<sub>2</sub> [36,37]. In the presence of conjugated FAs, these reactions generate NO<sub>2</sub>-FAs in the gastric compartment [10,12]. Pioneering work by Lima *et al.* recognized the formation of a nitrated LA in the stomach, with the levels in circulation increasing during the postprandial state [19,20]. In retrospect, although initially identified as NO<sub>2</sub>-LA, it is likely that those observations would have corresponded to NO<sub>2</sub>-CLA. The authors compared endogenous NO<sub>2</sub>-LA with synthetic standards and reported differences in spectra and retention times, recognizing that these could be due to different positional isomers *in vivo* [20]. Furthermore, the analysis of NO<sub>2</sub>-FA expanded to include NO<sub>2</sub>-LA-containing cholesterol esters. The evaluation of these species is more complex and its structural characteristics have yet to be fully elucidated [19].

The relevance of gastric NO<sub>2</sub>-CLA formation stemmed from studies in mice and rats showing that coadministration of <sup>15</sup>NO<sub>2</sub> and CLA resulted in the appearance of <sup>15</sup>NO<sub>2</sub>-CLA in plasma, tissue, and urine [10]. Moreover, gastric NO<sub>2</sub>-CLA formation is able to induce expression of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-dependent gene heme-oxygenase-(HO)-1 in colon epithelial cells, reinforcing the concept that diet-dependent formation of NO<sub>2</sub>-FA actively participates in signaling and tissue-protective mechanisms [10]. These studies were later translated into humans with oral coadministration of CLA (3 g) and 20 mg <sup>15</sup>NO<sub>2</sub>, resulting in a rapid increase of <sup>15</sup>NO<sub>2</sub>-CLA and a peak concentration (C<sub>max</sub>) in plasma at 1 h of 25 nM [12]. Basal levels of plasma NO<sub>2</sub>-CLA in human healthy volunteers are ~1 nM [10,12]. To add context to the levels derived from dietary sources and formed during digestion, animals administered subcutaneously with a pharmacological dose of 2 mg/kg/day using osmotic minipumps had steady-state concentrations of plasma NO<sub>2</sub>-OA of around 6 nM [38]. Based on area under the curve, similar exposures are obtained between the dietary and pharmacological approaches further highlighting the potential for diet-based interventions that modulate the levels of NO<sub>2</sub>-CLA.

Besides gastric formation, the characterization and description of endogenous NO<sub>2</sub>-FA formation have been challenging. The first observation of endogenous NO<sub>2</sub>-CLA formation *in vivo* occurred in a murine model of focal cardiac I/R [30]. In this same model, exogenous administration of

NO<sub>2</sub>-OA resulted in significant protection against I/R injury, with a marked preservation of left ventricular function and significant reduction in infarct size. After that observation, efforts focused on the evaluation of NO<sub>2</sub>-CLA formation during inflammation. In cell culture, macrophage activation in the presence of CLA results in significant NO<sub>2</sub>-CLA formation [10,23,39]. This formation required the generation of •NO and was abolished by the pharmacological inhibition of •NO synthase. While •NO was required, addition of isotopically labeled nitrite (<sup>15</sup>NO<sub>2</sub><sup>-</sup>) resulted in the incorporation of <sup>15</sup>N in NO<sub>2</sub>-CLA, without modifying the overall yields [39]. This indicated that in cell culture, CLA nitration was mostly dependent on •NO auto-oxidation reactions and not NO<sub>2</sub><sup>-</sup> acidification or reactions forming peroxyxynitrite. These observations were translated into an animal model of sterile sepsis to show that peritoneal inflammation formed NO<sub>2</sub>-CLA. Using <sup>18</sup>O- and <sup>15</sup>N-labeling strategies, this work again revealed that these reactions were not related to NO<sub>2</sub><sup>-</sup> acidification *in vivo* but to the formation and auto-oxidation of •NO. Similar to cell culture experiments, *in vivo* oxidation of •NO resulted in the formation of symmetrical N<sub>2</sub>O<sub>3</sub> and concomitant formation of •NO<sub>2</sub>. These reactions were specific to CLA and did not result in nitration of LA or other FAs. This work was extended using intraperitoneal zymosan A from *Saccharomyces cerevisiae* to induce inflammation [39]. The local formation of NO<sub>2</sub>-CLA decreased the formation of proinflammatory cytokines and inhibited leukocyte recruitment, suggesting that NO<sub>2</sub>-CLA acts as an adaptive mediator to control inflammation and protect neighboring tissues through the activation of Nrf2-dependent genes [23]. The therapeutic effects of NO<sub>2</sub>-FAs have been demonstrated in many preclinical animal models (Table 1), but the question regarding the extent of the protective effect of endogenously produced NO<sub>2</sub>-CLA at the site of inflammation, injury, or I/R has not been completely addressed yet.

### NO<sub>2</sub>-FA Distribution and Metabolism

Most of the studies characterizing NO<sub>2</sub>-FAs measured the concentrations of the free acid form in plasma [17,18,21,22,38]. It has become clear that most of the NO<sub>2</sub>-FAs are absorbed at the enterocyte level and packaged into chylomicrons that reach the systemic circulation via the thoracic lymphatic duct and left subclavian vein [40]. In animals, bolus oral administration of NO<sub>2</sub>-OA results in esterified levels that are 40 times greater than the levels of the free acid form [40]. This is relevant as plasma levels of free acid NO<sub>2</sub>-CLA concentrations in healthy human volunteers remain stable around 1–3 nM [12]. Because of technical challenges related to the stability of NO<sub>2</sub>-CLA under hydrolysis conditions, the level of esterified NO<sub>2</sub>-CLA has yet to be determined in humans.

The distinction and the consequences of the NO<sub>2</sub>-FAs being distributed through lipoproteins (mainly chylomicrons and very low-density lipoproteins) are far reaching, as tissue delivery depends on the local activity of lipoprotein lipases, as is the case for other FAs. The activity of lipoprotein lipases (LPLs) is tightly regulated by angiopoietin-like 4 (Angptl4) and is highest in tissues that rely on FAs as energy sources like heart, kidney, and muscle, or to store FAs as triglycerides and provide heat (white and brown adipose tissue, respectively) [41]. Importantly, the reported expression and activity of LPL correlate with the distribution of tissue radioactivity in rats orally administered with [<sup>14</sup>C]-NO<sub>2</sub>-OA [42]. LPL is synthesized by parenchymal tissue and transported to the lumen of capillaries. Hydrolysis of FAs from triglycerides is catalyzed when LPL is bound to glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) [43]. The accumulation of [<sup>14</sup>C]-NO<sub>2</sub>-OA in adipose tissue indicates that adipocytes act as reservoirs as well as a buffering system that maintains NO<sub>2</sub>-FA levels in plasma at constant levels [42,44].

Adipose tissue releases NO<sub>2</sub>-FAs in the free FA form into the blood, which are then transported back to the liver tightly bound to albumin. Considering that cultured adipocytes actively reduce

Table 1. NO<sub>2</sub>-FA Evaluation in Preclinical Animal Models<sup>a</sup>

Disease state	Animal	Disease model	Dose	Duration	Route of admin	Outcomes	Refs
ALS	Female B6SJL-TgN (SOD1-G93A) 1Gur mice	Onset of disease @ 90 d followed by treatment until 140 d	16 mg/kg/day	7.14 wk	SC injection (3x/wk)	NO <sub>2</sub> -OA crossed the BBB and was neuroprotective in this ALS model	[80]
Atherosclerosis	8-wk-old apoE <sup>-/-</sup> mice	Western diet	8 mg/kg/day	3 wk	SC minipump	NO <sub>2</sub> -OA reduced atherosclerotic lesion formation via decreasing inflammation, macrophage infiltration and limiting the expression of adhesion molecules	[81]
Atrial fibrosis	C57BL/6J mice	AngII infusion via mini pump (1.5 ng/g/min)	6 mg/kg/day	2 wk	SC minipump	NO <sub>2</sub> -OA decreased the Ang-II-induced fibrotic response in heart	[82]
Atrial fibrosis and fibrillation						NO <sub>2</sub> -OA decreased Ang-II-induced vulnerability for atrial fibrillation and inhibited atrial fibrosis	[83]
Breast cancer	6-wk-old female athymic nude mice	MDA-MB-231 xenograft tumor growth; NO <sub>2</sub> -OA started once tumor size was 50–100 mm <sup>3</sup>	7.5 mg/kg/d	4 wk	Oral gavage	NO <sub>2</sub> -OA mediates <i>in vivo</i> growth suppression of MDA-MB-231 cells with no overt toxic effects	[72]
Cardiac I/R – MI	8–12-wk-old C57/Bl6 mice	I/R: 30 min unilateral ischemia, 24 h reperfusion	6.6 mg/kg	At time of reperfusion	IP	NO <sub>2</sub> -OA has protective effects in cardiac I/R resulting in decreased infarct size and improved left ventricular function in all treatment regimens	[30]
				15 min prior to reperfusion	IP		
				3 d prior to ischemia	SC minipump		
Diabetes	8–10-wk-old C57BL/6J or Lep <sup>ob</sup> (ob/ob) male mice	Genetic model of obesity and insulin resistance on normal chow	8 mg/kg/d	4 wk	SC minipump	NO <sub>2</sub> -OA normalized hyperglycemia in diabetic mice. Plasma levels of 30 nM were enough to exert a pharmacological effect	[84]
Hypertension	8–10-wk-old C57BL/6J mice	Ang II infusion	5 mg/kg/day	2 wk	SC mini-pump	NO <sub>2</sub> -OA lowers BP by acting as an antagonist of Ang-II-induced hypertension	[55]
		Pre-existing hypertension: Ang II injection	1.25, 2.5, 5, 10, 20 mg/kg	10 min before or 3 d after Ang II delivery	IV – jugular infusion	Dose-dependent reduction in BP. While PPAR $\gamma$ agonist had no effect on BP reduction by NO <sub>2</sub> -OA	
	C57BL/6	Ang II infusion via mini pump at 1 mg/kg/d	5 mg/kg/d	3 days after Ang II infusion	SC minipump	NO <sub>2</sub> -OA protects against Ang-II-induced hypertension and is mediated via the inhibition of soluble epoxide hydrolase	[56]
Inflammation (multiorgan sepsis)	8–10-wk-old male C57BL/6 mice	<i>Escherichia coli</i> -induced septic shock (single IP injection of 10 mg/kg); 18 hr	0.2 mg/kg/d	48 h before LPS challenge of 18 h	SC minipump	NO <sub>2</sub> -OA protects against endotoxin-induced endotoxemia and multiorgan injury in mice	[85]

(continued on next page)

Table 1. (continued)

Disease state	Animal	Disease model	Dose	Duration	Route of admin	Outcomes	Refs
Inflammation (pulmonary and sepsis)	8-wk-old male C57BL/6J and 5-LO-deficient mice	LPS (20 mg/kg, IP); 16 h	6.6 mg/kg	1, 4 h before and 4 h after LPS	IP	NO <sub>2</sub> -OA attenuates LPS-induced neutrophil and monocyte mobilization, irreversibly inhibits 5-LO and inhibits lung injury	[86]
Inflammation (skin)	6–12-wk-old female Balb/c mice	CHS-sensitization with 0.5% DNFB, FITC, or oxazolone	0.84 mg/kg	18 h prior to skin insult	topical	Topical application of NO <sub>2</sub> -OA augments CHS response	[75]
	and male and female FoxP3 <sup>DTR</sup> mice			18 h prior to skin insult	SC injection	SC injection of NO <sub>2</sub> -OA inhibits skin inflammation in ACD	[74]
Inflammation (vascular)	C57BL/6J mice	Tail vein injection of LPS (0.5 mg/kg LPS); 3 h	5 mg/kg/d	3 d	SC minipump	NO <sub>2</sub> -OA decreased vascular inflammation by disrupting TLR4 signaling and inhibiting leukocyte adhesion	[87]
Inflammatory bowel disease	7–8-wk-old female BALB/c mice	DSS-induced (2% in drinking water for 7 d)	0.5 or 5 mg/kg/d	7 d	SC minipump	NO <sub>2</sub> -OA reduced disease index, prevented colon shortening and the increase in p65 expression by increasing PPAR $\gamma$ expression	[88]
Kidney – diabetic nephropathy	12-wk-old Lepr <sup>db/db</sup> (db/db) and Lepr <sup>db/m</sup> (db/m)	Genetic model; coupled NO <sub>2</sub> -OA with losartan	5 mg/kg/d	2 wk	SC minipump	NO <sub>2</sub> -OA or losartan alone mildly decreased kidney injury. However, when treatments were combined, the diabetic renal injury was reversed	[89]
Kidney – nephropathy	Male BALB/c mice	ADR-induced nephropathy; mice sacrificed 7 d after 10 mg/kg ADR injection	5 mg/kg/day	2 d before ADR single injection	SC minipump	NO <sub>2</sub> -OA protects against ADR nephropathy by decreasing inflammation and reactive species generation	[90]
Kidney – Renal I/R	3-mo-old male B6129SF2/J mice	I/R: 30 min warm, bilateral ischemia, 24 h reperfusion	0.5 mg/kg	Starting 1 h after ischemia, every 6 h for 24 h	IP	Delayed administration of NO <sub>2</sub> -OA attenuates renal I/R injury in the mouse likely via inhibition of the inflammatory response	[91]
NAFLD/NASH	8-wk-old male C57BL/6J and apoE <sup>-/-</sup> mice	WD (42% fat, TD.88137) NASH (40% fat, D17010103)	5 or 8 mg/kg/d	12 wk	SC minipump	NO <sub>2</sub> -OA protects against NASH-diet-induced liver damage, hepatomegaly and steatohepatitis	[70]
	6–8-wk-old C57BL/6J mice	HFD (60% fat; D12492)	8 mg/kg/d	6 wk	SC minipump	NO <sub>2</sub> -OA protects against obesity-induced insulin resistance and steatosis	[92]
Obesity	4-mo-old obese Zucker rats – fa/fa mutation in leptin receptor	Genetic model on normal chow	0.0075 mg/kg/d	2 wk	SC minipump	NO <sub>2</sub> -OA decreased plasma triglyceride levels, normalizes plasma nonesterified free FAs and increases plasma high-density lipoproteins in obese Zucker rats. NO <sub>2</sub> -FA may be a safe and effective therapeutic for obesity	[93]

Table 1. (continued)


Disease state	Animal	Disease model	Dose	Duration	Route of admin	Outcomes	Refs
Pulmonary arterial hypertension	8–10-wk-old C57BL/6J mice	Hypoxia (10% O <sub>2</sub> ) for 28 d on normal chow	8 mg/kg/d	2 and 4 wk	SC mini-pump	NO <sub>2</sub> -OA attenuated hypoxia-induced pulmonary hypertension	[94]
	6–8-wk-old C57BL/6J mice	HFD (60% fat; D12492)	8 mg/kg/d	6.5 wk	SC minipump	NO <sub>2</sub> -OA protects against obesity-induced insulin resistance and PAH	[95]
Vascular injury	6–8-wk-old C57BL/6 mice	Wire injury of femoral artery	2 mg/kg/d	3 wk	SC minipump	NO <sub>2</sub> -OA inhibited neointimal hyperplasia after wire-induced femoral artery injury via HO-1-dependent mechanisms	[38]
Ventral hernia	10–12-wk-old female Sprague–Dawley rats	Microparticle delivery of NO <sub>2</sub> -OA in a ventral hernia rat model	~1200 pmol/scaffold ( <i>in vitro</i> assessment)	8 wk	Scaffold implantation	NO <sub>2</sub> -OA repaired the abdominal wall and increased angiogenesis	[96]

<sup>a</sup>Abbreviations: ACD, allergic contact dermatitis; ADR, adriamycin; ALS, amyotrophic lateral sclerosis; BBB, blood–brain barrier; CHS, contact hypersensitivity; DNFB, 1-fluoro-2,4-dinitrobenzene; DSS, dextran sodium sulfate; HFD, high-fat diet; IP, intraperitoneal; IV, intravenous; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; LO, lipoxygenase; LPS, lipopolysaccharide; MI, myocardial infarction; SC, subcutaneous; WD, Western diet.

NO<sub>2</sub>-FAs into their corresponding nonelectrophilic nitroalkanes [42,44], the extent of fat release of active nitroalkenes has yet to be established. While albumin represents the most abundant thiol in plasma (~600 μM, 75% Cys 34 in the reduced state), representing a potential sink for NO<sub>2</sub>-FA in circulation, it has been shown that the reaction with Cys34 is minimal [26]. Instead, NO<sub>2</sub>-FAs actively bind to the hydrophobic pockets present in albumin and are thereby stabilized and transported [26,45]. Once in the liver, these bioactive lipids exert their signaling actions, are recycled and packed into VLDL, metabolized through β and ω oxidation, or inactivated through the activity of prostaglandin reductase 1 [46]. It remains to be established whether the metabolites produced by the liver are excreted through bile or returned to the circulation for renal elimination. While 35% of orally administered [<sup>14</sup>C]-NO<sub>2</sub>-OA is disposed of via urinary excretion, it is unclear whether the remaining 65% is not absorbed or actively excreted in the feces through the biliary system [11,42].

### Endothelium and Lipid Metabolism

The endothelium provides a physical barrier between blood and tissues. This single layer of endothelial cells essentially acts as an overall gatekeeper that communicates signals between blood and tissue by actively or passively transporting vasoactive biomolecules into and out of the circulation. Although it has not been studied in detail, data suggests that NO<sub>2</sub>-FAs are transported through the same mechanisms as FAs via FA-binding proteins (FABPs) and translocases. The delivery of lipids to tissues and their consequent metabolism is tightly regulated by endothelial cells [47]. The docking protein GPIHBP1 anchors LPL to the endothelial lumen, to temporarily immobilize and hydrolyze FAs off triglycerides carried by transporting lipoproteins (chylomicrons and VLDL) [48,49]. This activity is tissue specific and differentially modulated during fed/fasting states [50]. During the fed state, higher LPL activity and GPIHBP1 expression in adipose tissue facilitate directed transport to storage areas, while fasting promotes a higher delivery to muscle, heart, and kidney (Figure 3). This mechanism of distribution also applies to NO<sub>2</sub>-FAs, where [<sup>14</sup>C]-labeling studies have shown preferential localization to adipose tissue, heart, liver, and kidney [42]. Once released from lipoproteins, FAs are actively transported across the endothelial cells by the fatty acid transporter CD36 in coordination with FABPs [51]. NO<sub>2</sub>-FAs exert signaling actions



Trends in Endocrinology & Metabolism

**Figure 3. Formation and Biodistribution of NO<sub>2</sub>-FA.** NO<sub>2</sub>-CLA formation is promoted under the acidic conditions found in the stomach through the reaction of dietary nitrite-derived radicals and CLA (usually found esterified in triglycerides). For therapeutic purposes, NO<sub>2</sub>-FAs can also be administered orally as a drug as is the case for CXA-10 (Complexa Inc. – currently undergoing Phase II clinical trials). Through the activity of lipases, triglycerides are hydrolyzed and NO<sub>2</sub>-FAs are released and

(Figure legend continued at the bottom of the next page.)

not only at target tissues, but also endothelial cells and vascular smooth muscle cells found in larger arteries. Distinctly, after reaching adipose tissue, NO<sub>2</sub>-FAs become esterified and part of a larger pool of releasable FAs. The extent to which fat tissue contributes to buffering systemic NO<sub>2</sub>-FAs through adipocyte-controlled release has yet to be established but systemic levels is a maintained even after days of discontinuing administration suggesting that adipose tissue the main reservoir. NO<sub>2</sub>-FAs are mobilized from adipocytes through the activity of adipose triglyceride lipase (ATGL) and transported back to the liver bound to albumin (Figure 3).

### NO<sub>2</sub>-FAs Regulate Vascular Tone

The regulatory actions exerted by NO<sub>2</sub>-FAs on endothelial cells have not been explored as extensively as other cell types and tissues. Among these, NO<sub>2</sub>-FAs regulate vascular tone by phosphorylating endothelial NO synthase (eNOS) and increasing eNOS protein expression in endothelial cells, which ultimately enhances •NO bioavailability [52]. Additionally, NO<sub>2</sub>-FAs significantly enhance Nrf2-dependent HO-1 expression and activity in endothelial and vascular smooth muscle cells [38,52,53], and thereby increases CO, which is also a potent endogenous vascular modulator via guanylyl cyclase activation. Endothelin (ET)-1 is a vasoconstrictor and antagonizes the vasodilating effects of •NO. NO<sub>2</sub>-FAs induce ET-1 clearance through the Nrf2-dependent increase of endothelin receptor B expression in vascular ECs [54]. These protective effects in cell culture translate to hypertension models in mice. NO<sub>2</sub>-FAs decrease angiotensin (Ang) II-induced blood pressure in mice [55,56]. These protective effects have been attributed to NO<sub>2</sub>-FA covalently adducting Ang II type 1 receptor which interferes with G-protein-coupled receptor signaling and limits calcium flux in vascular smooth muscle cells [55]. Subsequent studies also revealed that NO<sub>2</sub>-FA inhibits soluble epoxide hydrolase (sEH), resulting in the accumulation of endogenous vasodilators [56]. By increasing endogenous vasodilation mediators and suppressing the vasoconstrictive effects of ET-1, NO<sub>2</sub>-FAs are able to regulate blood pressure. Most of these findings can be attributed to a regulation of EC function or a consequence of the EC exposition to NO<sub>2</sub>-FAs during their transport across the endothelial barrier to reach parenchymal or smooth muscle cells.

### Reactivity Explains Signaling

The nitroalkene group present in NO<sub>2</sub>-CLA and NO<sub>2</sub>-OA is electrophilic and actively participates in reversible Michael addition reactions [24,26,57]. Main targets are soft nucleophiles such as cysteine present in proteins and/or GSH, but proteomic approaches have also shown the formation of histidine adducts [58]. Glutathione, a tripeptide, is the most abundant cysteine-containing molecule in cells. While many endogenous electrophiles react covalently with these targets, these reactions are either irreversible or display small K<sub>off</sub> reaction constants resulting in very slow elimination reactions [58]. By contrast, NO<sub>2</sub>-FAs display higher on and off reaction rates resulting in a highly movable pool of intracellular NO<sub>2</sub>-FAs characterized by rapid addition and elimination

---

absorbed together with other FAs by enterocytes, packed into chylomicrons as triglycerides and moved into the circulation via the lymphatic system. (A) Once the chylomicrons reach the capillaries, the NO<sub>2</sub>-FAs are cleaved off the triglycerides by the activity of lipoprotein lipases in a process that requires the presence of docking protein GPIHBP1. The released NO<sub>2</sub>-FAs can bind to fatty acid transporters (e.g., CD36) or diffuse into the endothelial cells and reach the parenchymal cells, such as cardiomyocytes. Heart, kidney, muscle, liver, and adipose tissue are among the main targets. Once the NO<sub>2</sub>-FAs reach the target cells, they participate in signaling pathways via post-translational modifications of proteins, are metabolized, and then enzymatically inactivated. (B) Hydrophilic metabolites of NO<sub>2</sub>-FAs, including dicarboxylic acid derivatives, β-oxidation products, mercapturic acids, and cysteine adducts, are filtered in the kidney and eliminated in the urine. (C) NO<sub>2</sub>-FAs that reach the adipose tissue are re-esterified into triglycerides for storage. Degradation products formed during tissue metabolism and NO<sub>2</sub>-FAs released from adipocytes through ATGL activity reach the circulation where they bind to albumin and are transported and delivered to the liver for excretion or filtered into urine by the kidneys. (D) Alternatively, NO<sub>2</sub>-FAs that reach the liver can be reincorporated into triglycerides, assembled in the endoplasmic reticulum and Golgi compartments into VLDL particles, and mature VLDL particles containing Apo B, E, and CIII released to circulation and distributed systemically to target tissues. This initiates a new cycle of delivery, signaling, inactivation, metabolism, and elimination. Finally, the liver clears remaining LDL particles and remnant chylomicrons through selective uptake and breakdown. Abbreviations: Apo, apolipoprotein; ATGL, adipose triglyceride lipase; GPIHBP1, glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LPL, lipoprotein lipase; NO<sub>2</sub>-CLA, nitro-conjugated linoleic acid; NO<sub>2</sub>-FA, nitro-fatty acid; OAT, organic acid transporter; TG, triglyceride; VLDL, very low density lipoprotein.

kinetics. Ultimately, the reactions with cysteines are the ones that have been proven to activate or deactivate signaling pathways and enzymatic activities [59].

### Rationale for Using NO<sub>2</sub>-OA as a Potential Therapeutic

NO<sub>2</sub>-OA is a minor endogenous NO<sub>2</sub>-FA and often remains undetectable in tissues and body fluids. Yet, most of the signaling and pharmacology has been performed with it. Why?

This is closely related to the findings and evolution of the field throughout the years and the historic use of OA and LA as nitration substrates. The first evidence of the nitration of lipids came from toxicological work performed by Pryor and Lightsey to understand the impact of •NO<sub>2</sub> exposure to the lungs [60]. These studies focused on low and high •NO<sub>2</sub> levels and demonstrated that nitration occurred only at a high concentration of •NO<sub>2</sub> in both single and methylene interrupted double bonds [60–62]. Studies on the mechanisms and nitration products were later expanded using both OA and LA as substrates [60,63,64]. Initially, nitration of LA was examined, which was then followed by reports of NO<sub>2</sub>-OA detection [17,21,22]. While •NO<sub>2</sub> also adds to nonconjugated double bonds, as is the case for OA and LA, the resulting intermediate radical products are predicted to be highly unstable. Under biological conditions, most of these formed radical intermediates will undergo •NO<sub>2</sub> elimination and induce *cis-trans* isomerization before they can be stabilized (Figure 2C). This is the main difference with CLA, where additional stability of the NO<sub>2</sub>-CLA intermediate radical is achieved through resonance structures, greatly increasing the nitration yields when compared to OA and LA.

While, initially, formation of both NO<sub>2</sub>-OA and NO<sub>2</sub>-LA was reported, there was a preference of NO<sub>2</sub>-OA over NO<sub>2</sub>-LA due to less complicated organic synthesis methods and higher stability while maintaining similar signaling actions and reactivity towards thiols [24,26,65]. Thus, NO<sub>2</sub>-OA was selected as the prototypical NO<sub>2</sub>-FA and used in most of the preclinical studies (Table 1). Based on these animal models and specific signaling activity, the regio-specific isomer 10-NO<sub>2</sub>-OA was selected to be developed as a drug candidate to treat inflammatory and fibrotic diseases [66]. It was only years later and supported by more advanced MS techniques that the NO<sub>2</sub>-CLA was discovered as the main endogenous species [10]. Despite eliciting similar *in vitro* signaling responses, NO<sub>2</sub>-CLA has characteristics that differentiate it from NO<sub>2</sub>-OA and NO<sub>2</sub>-LA. In particular, NO<sub>2</sub>-CLA presents two electrophilic sites with different K<sub>on</sub> and K<sub>off</sub>, which are currently being explored [26].

### NO<sub>2</sub>-FAs Signaling

The signaling actions of NO<sub>2</sub>-FAs go beyond regulating vascular tone, modulating responses in endothelial, parenchymal, and stromal cells. Since the signaling of NO<sub>2</sub>-FAs is largely driven by its reaction with target cysteines, numerous signaling events and enzymatic activities are modulated. While common pathways include activation of Nrf2, induction of heat shock responses (HSR), and inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), other more subtle signaling events are cell and tissue specific. Hierarchical transcriptome clustering analysis of cultured endothelial cells treated with NO<sub>2</sub>-OA revealed that 363 genes were increased and 103 decreased. Of the top 10 mRNA transcripts, eight originate from the heat shock protein family, which had the greatest induction. These findings were validated by qPCR, which showed a maximum induction occurring between 4 h and 8 h in cultured endothelial cells [53]. In response to stress, HSR upregulates transcriptional activity to protect proteins, including expression of folding chaperones and the induction of programs that remove misfolded proteins [67–69]. These microarray data reflect the magnitude of pathway engagement obtained in just cultured endothelial cells. More recently, RNA-sequencing analysis was performed on a model of steatosis and fibrosis using liver from control diet and NASH diet with vehicle, parent nonelectrophilic OA, and electrophilic NO<sub>2</sub>-OA. The unbiased analysis of liver gene expression revealed that NO<sub>2</sub>-OA treatment for 12 weeks, once steatosis was established, reversed NASH

diet-induced atherosclerotic, fibrotic, inflammatory, lipid metabolism, and stellate cell activation pathways that are involved in the progression to steatohepatitis. More specifically, NO<sub>2</sub>-OA suppressed hepatic fibrosis genes such as transforming growth factor (TGF)β-1–3, TGFβ receptor 1, tissue inhibitor of metalloproteinase 1 and 2 compared to the nonelectrophilic OA-treated NASH group. The treatment of NO<sub>2</sub>-OA significantly decreased proinflammatory genes that regulate chemokines, inflammasomes, NF-κB, and Toll-like receptor (TLR)4 signaling pathways. Lipid metabolism is significantly modulated by NO<sub>2</sub>-OA with the suppression of lipogenic genes (monoacylglycerol o-acyltransferase 2, stearyl-CoA desaturase-2, and sterol regulatory element-binding transcription factor 1) and induction of lipolytic pathways including carnitine palmitoyltransferase (CPT)-1α, CPT-2 and peroxisome proliferator-activated receptor gamma coactivator 1-α [70].

The actions of NO<sub>2</sub>-FA are protective in an array of preclinical animal models. The observed effects in the preclinical animal models (summarized in Table 1) contrast the technical challenges to identify the mechanisms of actions in all of these models. The pleiotropic effects displayed by the NO<sub>2</sub>-FAs are closely related with their reactivity. While the activation of Nrf2 and HSR pathways as well as the inhibition of NF-κB are commonly observed actions in the different disease animal models, the relevance of alternative mechanisms of action should always be considered. Inhibition of xanthine oxidase, sEH, Ang II receptor, Rad51, stimulator of interferon genes (STING), and activation of peroxisome proliferator-activated receptor (PPAR)-γ, among others, have been described as subcellular targets of NO<sub>2</sub>-FAs [55,56,58,71–73]. The engagement of these pathways has gained relevance under certain pathophysiological conditions and need to be addressed individually. This is perhaps the most challenging aspect related to NO<sub>2</sub>-FAs. As summarized in Table 1, in most cases, the therapeutic dose for NO<sub>2</sub>-FAs ranges between 2 and 8 mg/kg/day. NO<sub>2</sub>-FAs have been mostly administered using oral and subcutaneous routes, while topical and intravenous administration has also been tested [55,74,75]. Considering that systemic distribution largely relies on lipoprotein transport, the route of administration is an important variable to be considered in every study design. An important caveat to the routes of NO<sub>2</sub>-FA administration is the topical application that can result in unwanted dysregulation of immune responses. Similar effects are observed with the therapeutic drug dimethyl fumarate used for the treatment of multiple sclerosis [76]. Skin contact with dimethyl fumarate results in severe dermatitis [77]. While this review does not focus on specific disease states and the potential mechanisms behind the protective effects [58,78,79], Table 1 shows a summary of dose and route of administration, disease condition, and therapeutic outcome.

### Concluding Remarks and Future Perspectives

In both transcriptome data sets, *in vitro* endothelial cells and *in vivo* liver NASH model, only a small fraction of the pathways, described above, have been closely examined to determine the mechanistic actions of NO<sub>2</sub>-FAs. The NO<sub>2</sub>-FA field is constantly evolving as new pathways involved in the metabolism, absorption, trafficking and signaling are being discovered (see Outstanding Questions). These big transcriptome data, coupled with ongoing lipidomic, proteomics- and MS-based approaches, will help prioritize and guide which pathways to pursue. As previously discussed, the data is likely to be cell- and tissue-type specific. The simplistic view of ‘one drug–one target’ strategy will not work for lipid electrophiles given its pleiotropic characteristics. The ‘one drug–multiple targets’ approach with NO<sub>2</sub>-FAs might provide responses to the unmet clinical needs, particularly for diseases that display multi-factorial pathogenesis.

### Acknowledgments

We would like to thank Ms. Sonia Salvatore for input and graphic design. This work was supported by R01-GM125944 and R01-DK112854 (F.J.S), AHA 17GRN33660955 (F.J.S), P01-HL103455 (N.K.H.K.), and University of Pittsburgh Medical Center Competitive Medical Research Fund Award (N.K.H.K.).

### Outstanding Questions

Does the endogenously generated NO<sub>2</sub>-CLA in the gastric compartment induce protective signaling actions? Do these preferentially target certain tissues given its biodistribution mechanism?

Could gastric NO<sub>2</sub>-CLA formation be a viable dietary alternative to treat chronic inflammatory diseases?

What is the impact of NO<sub>2</sub>-CLA stored in adipocytes on signaling and systemic levels?

What are other signaling pathways engaged by NO<sub>2</sub>-FAs? Are there clear differences between NO<sub>2</sub>-OA and NO<sub>2</sub>-CLA *in vivo*?

So far, CLA has been identified as the preferred endogenous substrate for FA nitration. The other major source of conjugated FAs that can be obtained from the diet is CLnA. Is CLnA nitrated? Is CLnA a better substrate than CLA?

*In vitro* treatment concentrations are usually 1–3 μM and *in vivo* levels are 1–3 nM. While *in vivo* levels are in a pseudo-steady state with endogenous cysteines, exogenously added NO<sub>2</sub>-FAs rapidly decrease in concentration given metabolism and thiol addition reactions. How should the concentrations between *in vitro* experiments and *in vivo* levels be reconciled to provide bridging between the different settings?

**Disclaimer Statement**

F.J.S has financial interest in Complexa Inc. N.K.H.K. has no conflicts of interest to declare.

**References**

- Burr, G.O. and Burr, M.M. (1973) Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. *Nutr. Rev.* 31, 248–249
- Spector, A.A. and Kim, H.Y. (2015) Discovery of essential fatty acids. *J. Lipid Res.* 56, 11–21
- Holman, R.T. (1998) The slow discovery of the importance of omega 3 essential fatty acids in human health. *J. Nutr.* 128, 427S–433S
- Barr, L.H. *et al.* (1981) Essential fatty acid deficiency during total parenteral nutrition. *Ann. Surg.* 193, 304–311
- Dennis, E.A. and Norris, P.C. (2015) Eicosanoid storm in infection and inflammation. *Nat. Rev. Immunol.* 15, 511
- Belury, M.A. (2002) Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. *Annu. Rev. Nutr.* 22, 505–531
- Gómez-Cortés, P. *et al.* (2018) Milk fatty acids and potential health benefits: an updated vision. *Trends Food Sci. Technol.* 81, 1–9
- Yuan, G.-F. *et al.* (2014) Conjugated linolenic acids and their bioactivities: a review. *Food Funct.* 5, 1360–1368
- Raimondi, S. *et al.* (2016) Conjugated linoleic acid production by bifidobacteria: screening, kinetic, and composition. *Biomed. Res. Int.* 2016, 8654317
- Bonacci, G. *et al.* (2012) Conjugated linoleic acid is a preferential substrate for fatty acid nitration. *J. Biol. Chem.* 287, 44071–44082
- Salvatore, S.R. *et al.* (2013) Characterization and quantification of endogenous fatty acid nitroalkene metabolites in human urine. *J. Lipid Res.* 54, 1998–2009
- Delmastro-Greenwood, M. *et al.* (2015) Nitrite and nitrate-dependent generation of anti-inflammatory fatty acid nitroalkenes. *Free Radic. Biol. Med.* 89, 333–341
- Ferrer-Sueta, G. *et al.* (2018) Biochemistry of peroxynitrite and protein tyrosine nitration. *Chem. Rev.* 118, 1338–1408
- Tsunoda, M. *et al.* (2007) Determination of nitrocatecholamines in rat brain using high-performance liquid chromatography-peroxyoxalate chemiluminescence reaction detection. *J. Chromatogr. A* 1164, 162–166
- Tsunoda, M. *et al.* (2008) Oxidative stress increases 6-nitronorepinephrine and 6-nitroepinephrine concentrations in rat brain. *Biomed. Chromatogr.* 22, 572–574
- Fujii, S. and Akaike, T. (2013) Redox signaling by 8-nitro-cyclic guanosine monophosphate: nitric oxide- and reactive oxygen species-derived electrophilic messenger. *Antioxid. Redox Signal.* 19, 1236–1246
- Baker, P.R. *et al.* (2005) Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. *J. Biol. Chem.* 280, 42464–42475
- Baker, P.R. *et al.* (2004) Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. *Proc. Natl. Acad. Sci. U. S. A.* 101, 11577–11582
- Lima, E.S. *et al.* (2003) Cholesteryl nitrooleate, a nitrated lipid present in human blood plasma and lipoproteins. *J. Lipid Res.* 44, 1660–1666
- Lima, E.S. *et al.* (2002) Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. *Biochemistry* 41, 10717–10722
- Tsikas, D. *et al.* (2009) Specific GC-MS/MS stable-isotope dilution methodology for free 9- and 10-nitro-oleic acid in human plasma challenges previous LC-MS/MS reports. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci* 877, 2895–2908
- Tsikas, D. *et al.* (2009) Nitro-fatty acids occur in human plasma in the picomolar range: a targeted nitro-lipidomics GC-MS/MS study. *Lipids* 44, 855–865
- Villacorta, L. *et al.* (2018) *In situ* generation, metabolism and immunomodulatory signaling actions of nitro-conjugated linoleic acid in a murine model of inflammation. *Redox Biol.* 15, 522–531
- Baker, L.M. *et al.* (2007) Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. *J. Biol. Chem.* 282, 31085–31093
- Sawa, T. *et al.* (2010) Regulation of redox signaling involving chemical conjugation of protein thiols by nitric oxide and electrophiles. *Bioconjug. Chem.* 21, 1121–1129
- Turell, L. *et al.* (2017) The chemical basis of thiol addition to nitro-conjugated linoleic acid, a protective cell-signaling lipid. *J. Biol. Chem.* 292, 1145–1159
- Coles, B.F. and Kadlubar, F.F. (2003) Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? *Biofactors* 17, 115–130
- Akaike, T. *et al.* (2012) Regulation of redox signalling by an electrophilic cyclic nucleotide. *J. Biochem.* 153, 131–138
- Buchan, G.J. *et al.* (2018) Nitro-fatty acid formation and metabolism. *Nitric Oxide* 79, 38–44
- Rudolph, V. *et al.* (2010) Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. *Cardiovasc. Res.* 85, 155–166
- Hansen, R.E. *et al.* (2009) Quantifying the global cellular thiol-disulfide status. *Proc. Natl. Acad. Sci. U. S. A.* 106, 422–427
- Requejo, R. *et al.* (2010) Cysteine residues exposed on protein surfaces are the dominant intramitochondrial thiol and may protect against oxidative damage. *FEBS J.* 277, 1465–1480
- Schopfer, F.J. *et al.* (2009) Detection and quantification of protein adduction by electrophilic fatty acids: mitochondrial generation of fatty acid nitroalkene derivatives. *Free Radic. Biol. Med.* 46, 1250–1259
- Cosby, K. *et al.* (2003) Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. *Nat. Med.* 9, 1498–1505
- DeMartino, A.W. *et al.* (2019) Nitrite and nitrate chemical biology and signalling. *Br. J. Pharmacol.* 176, 228–245
- Lundberg, J.O. and Weitzberg, E. (2013) Biology of nitrogen oxides in the gastrointestinal tract. *Gut* 62, 616–629
- Rocha, B.S. *et al.* (2012) Intra-gastric nitration by dietary nitrite: implications for modulation of protein and lipid signaling. *Free Radic. Biol. Med.* 52, 693–698
- Cole, M.P. *et al.* (2009) Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury. *Circ. Res.* 105, 965–972
- Vitturi, D.A. *et al.* (2015) Convergence of biological nitration and nitrosation via symmetrical nitrous anhydride. *Nat. Chem. Biol.* 11, 504–510
- Fazzari, M. *et al.* (2019) Electrophilic fatty acid nitroalkenes are systemically transported and distributed upon esterification to complex lipids. *J. Lipid Res.* 60, 388–399
- Dijk, W. and Kersten, S. (2014) Regulation of lipoprotein lipase by Angptl4. *Trends Endocrinol. Metab.* 25, 146–155
- Fazzari, M. *et al.* (2017) Nitro-fatty acid pharmacokinetics in the adipose tissue compartment. *J. Lipid Res.* 58, 375–385
- Birrane, G. *et al.* (2019) Structure of the lipoprotein lipase–GPIIIBP1 complex that mediates plasma triglyceride hydrolysis. *Proc. Natl. Acad. Sci.* 116, 1723–1732
- Fazzari, M. *et al.* (2015) Generation and esterification of electrophilic fatty acid nitroalkenes in triacylglycerides. *Free Radic. Biol. Med.* 87, 113–124
- Turell, L. *et al.* (2013) The thiol pool in human plasma: the central contribution of albumin to redox processes. *Free Radic. Biol. Med.* 65, 244–253
- Vitturi, D.A. *et al.* (2013) Modulation of nitro-fatty acid signaling: prostaglandin reductase-1 is a nitroalkene reductase. *J. Biol. Chem.* 288, 25626–25637
- Fong, L.G. *et al.* (2016) GPIIIBP1 and plasma triglyceride metabolism. *Trends Endocrinol. Metab.* 27, 455–469
- Goldberg, I.J. (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J. Lipid Res.* 37, 693–707

49. Cryer, A. (1989) The role of the endothelium in myocardial lipoprotein dynamics. *Mol. Cell. Biochem.* 88, 7–15
50. Cushing, E.M. *et al.* (2017) Angiotensin-like 4 directs uptake of dietary fat away from adipose during fasting. *Mol. Metab.* 6, 809–818
51. Glatz, J.F.C. and Luiken, J. (2018) Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. *J. Lipid Res.* 59, 1084–1093
52. Khoo, N.K.H. *et al.* (2010) Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. *Free Radic. Biol. Med.* 48, 230–239
53. Kansanen, E. *et al.* (2009) Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. *J. Biol. Chem.* 284, 33233–33241
54. Kansanen, E. *et al.* (2017) Nitro-oleic acid regulates endothelin signaling in human endothelial cells. *Mol. Pharmacol.* 92, 481
55. Zhang, J. *et al.* (2010) Nitro-oleic acid inhibits angiotensin II-induced hypertension. *Circ. Res.* 107, 540–548
56. Charles, R.L. *et al.* (2014) Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. *Proc. Natl. Acad. Sci.* 111, 8167–8172
57. Batthyany, C. *et al.* (2006) Reversible post-translational modification of proteins by nitrated fatty acids *in vivo*. *J. Biol. Chem.* 281, 20450–20463
58. Schopfer, F.J. *et al.* (2011) Formation and signaling actions of electrophilic lipids. *Chem. Rev.* 111, 5997–6021
59. Bates, D.J. *et al.* (2009) Noncatalytic interactions between glutathione S-transferases and nitroalkene fatty acids modulate nitroalkene-mediated activation of peroxisomal proliferator-activated receptor gamma. *Biochemistry* 48, 4159–4169
60. Pryor, W.A. and Lightsey, J.W. (1981) Mechanisms of nitrogen dioxide reactions: initiation of lipid peroxidation and the production of nitrous Acid. *Science* 214, 435–437
61. Gallon, A.A. and Pryor, W.A. (1994) The reaction of low levels of nitrogen dioxide with methyl linoleate in the presence and absence of oxygen. *Lipids* 29, 171–176
62. Gallon, A.A. and Pryor, W.A. (1993) The identification of the allylic nitrite and nitro derivatives of methyl linoleate and methyl linolenate by negative chemical ionization mass spectroscopy. *Lipids* 28, 125–133
63. Napolitano, A. *et al.* (2004) Acid-induced structural modifications of unsaturated Fatty acids and phenolic olive oil constituents by nitrite ions: a chemical assessment. *Chem. Res. Toxicol.* 17, 1329–1337
64. Jain, K. *et al.* (2008) The mechanism of oleic acid nitration by <sup>•</sup>NO<sub>2</sub>. *Free Radic. Biol. Med.* 45, 269–283
65. Manini, P. *et al.* (2008) Chemistry of nitrated lipids: remarkable instability of 9-nitrooleic acid in neutral aqueous medium and a novel nitronitrate ester product by concurrent autoxidation/nitric oxide-release pathways. *J. Org. Chem.* 73, 7517–7525
66. Schopfer, F.J. *et al.* (2018) Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. *Nitric Oxide* 79, 31–37
67. Zügel, U. and Kaufmann, S.H. (1999) Role of heat shock proteins in protection from and pathogenesis of infectious diseases. *Clin. Microbiol. Rev.* 12, 19–39
68. Anckar, J. and Sistonen, L. (2007) Heat shock factor 1 as a coordinator of stress and developmental pathways. In *Molecular Aspects of the Stress Response: Chaperones, Membranes and Networks* (Csermely, P. and Vigh, L., eds), pp. 78–88, SpringerNew York
69. Buchman, T.G. *et al.* (1993) Induction of heat shock response leads to apoptosis in endothelial cells previously exposed to endotoxin. *Am. J. Phys. Heart Circ. Phys.* 265, H165–H170
70. Rom, O. *et al.* (2019) Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. *EBioMedicine* 41, 62–72
71. Kelley, E.E. *et al.* (2008) Nitro-oleic acid, a novel and irreversible inhibitor of xanthine oxidoreductase. *J. Biol. Chem.* 283, 36176–36184
72. Woodcock, C.-S.C. *et al.* (2018) Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. *J. Biol. Chem.* 293, 1120–1137
73. Hansen, A.L. *et al.* (2018) Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling. *Proc. Natl. Acad. Sci.* 115, E7768
74. Mathers, A.R. *et al.* (2017) Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. *Allergy* 72, 656–664
75. Mathers, A.R. *et al.* (2018) Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation. *Free Radic. Biol. Med.* 115, 31–42
76. Kappos, L. *et al.* (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet* 372, 1463–1472
77. Lammintausta, K. *et al.* (2010) An epidemic of furniture-related dermatitis: searching for a cause. *Br. J. Dermatol.* 162, 108–116
78. Rom, O. *et al.* (2018) Inflammatory signaling and metabolic regulation by nitro-fatty acids. *Nitric Oxide* 78, 140–145
79. Deen, A.J. *et al.* (2018) Regulation of stress signaling pathways by nitro-fatty acids. *Nitric Oxide* 78, 170–175
80. Trostchansky, A. *et al.* (2018) Profile of arachidonic acid-derived inflammatory markers and its modulation by nitro-oleic acid in an inherited model of amyotrophic lateral sclerosis. *Front. Mol. Neurosci.* 11, 131
81. Rudolph, T.K. *et al.* (2010) Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* 30, 938–945
82. Ambrozova, G. *et al.* (2016) Nitro-oleic acid modulates classical and regulatory activation of macrophages and their involvement in pro-fibrotic responses. *Free Radic. Biol. Med.* 90, 252–260
83. Rudolph, T.K. *et al.* (2016) Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation. *Cardiovasc. Res.* 109, 174–184
84. Schopfer, F.J. *et al.* (2010) Covalent peroxisome proliferator-activated receptor  $\gamma$  binding by nitro-fatty acids: Endogenous ligands act as selective modulators. *J. Biol. Chem.* 285, 12321–12333
85. Wang, H. *et al.* (2010) Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. *Am. J. Physiol. Ren. Physiol.* 298, F754–F762
86. Awwad, K. *et al.* (2014) Electrophilic fatty acid species inhibit 5-lipoxygenase and attenuate sepsis-induced pulmonary inflammation. *Antioxid. Redox Signal.* 20, 2667–2680
87. Villacorta, L. *et al.* (2013) Electrophilic nitro-fatty acids inhibit vascular inflammation by disrupting LPS-dependent TLR4 signalling in lipid rafts. *Cardiovasc. Res.* 98, 116–124
88. Borniquel, S. *et al.* (2010) Nitrated oleic acid up-regulates PPAR $\gamma$  and attenuates experimental inflammatory bowel disease. *Free Radic. Biol. Med.* 48, 499–505
89. Liu, Y. *et al.* (2013) Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. *Am. J. Physiol. Ren. Physiol.* 305, F1555–F1562
90. Liu, S. *et al.* (2013) Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. *Am. J. Physiol. -Renal Physiol.* 305, F1533–F1541
91. Liu, H. *et al.* (2008) Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. *Am. J. Physiol. Ren. Physiol.* 295, F942–F949
92. Khoo, N.K.H. *et al.* (2019) Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. *Redox Biol.* 22, 101132
93. Wang, H. *et al.* (2010) Effects of endogenous PPAR agonist nitro-oleic acid on metabolic syndrome in obese Zucker rats. *PPAR Res.* 2010, 601562
94. Klinke, A. *et al.* (2014) Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. *Am. J. Respir. Cell Mol. Biol.* 51, 155–162
95. Kelley, E.E. *et al.* (2014) Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high fat diet-induced obesity. *Cardiovasc. Res.* 101, 352–363
96. D'Amore, A. *et al.* (2017) Nitro-oleic acid (NO<sub>2</sub>-OA) release enhances regional angiogenesis in a rat abdominal wall defect model. *Tissue Eng. A* 24, 889–904